CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-087 / S-007

CHEMISTRY REVIEW(S)

SUPPLEMENTAL NDA	DUE DATE		1. ORGANIZATION 2. N		A NUMBER
CHEMIST'S REVIEW	07/16/01	HFD-530 21-087			
3. NAME AND ADDRESS OF APPLICANT		4. TYPE OF SUPPLEMENT			
Hoffman-La Roche		PAS			
340 Kingsland St.		5. DOCUMENT(S) NUMBERS DATED RECEIVED			
			NOWIDERS		03/14/01
Nutley, NJ 08902		BCD-007 OST IN I			
6. NAME OF DRUG	*	7. NONPROPRIETARY NAME			
Tamiflu capsules		Oseltamivir phosphate			
O SUDDI EMENT PROVIDES FOR:	9. AMENDMENTS/DATES				
re-tion of approved expiration dating fron	n 18 months t	s to 24 None			
months based on 24 months of real-time stab	months of real-time stability data for capsules				
for physician	sampling.	ing. IOW DISPENSED 12. RELATED IND/NDA/DMF(s)			
IU. I HARMACOLOGICAL					
Treatment of influenza A and B	X B	·			
13. DOSAGE FORM(S)		14. POTENCY (CIES)			
Capsules		75 mg/ capsule			
15. CHEMICAL NAME AND STRUCTURE			16. MEMORANDA		
See Package insert		None			
18. CONCLUSIONS AND RECOMMENDATE The information provided demonstration	ATIONS	there is little	e change i	n the dr	ug product
The information provided demons	su aics mai	- It is re	ecommend	ed that	this
for up to 24 months packaged in the		11 15 14 10 15 16 16 16 16 16 16 16 16 16 16 16 16 16	monthe h	e annro	ved.
supplemental application for extens	sion of expi	ration to 24	monus o	c appro	, , , , , , , , , , , , , , , , , , , ,
10 REVIEWER					
NAME	SIGNATUR gned electron	7	DATE OF DRAFT REVIEW 07/11/01		
[signed electronically in DFS]					
DFS CC LIST L DBoring		IO/TWu			mTox
L = Action Letter R L SMiller	R L P	M/GCarmouz	e	Micr	0
R = Review RL ONDC3 IO (CChe	n) B	iopharm			

REVIEW NOTES:

The following drug product material was packaged each into

Batches tested

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Dan Boring 9/6/01 04:43:00 PM CHEMIST

Stephen Paul Miller 9/14/01 11:27:04 AM CHEMIST